The treating physician has chosen Ventavis as a suitable long-term treatment for the patient 
Patient with primary pulmonary hypertension (i.e. Idiopathic Pulmonary Arterial Hypertension or Familial Pulmonary Arterial Hypertension) and classified as NYHA functional class III (NYHA = New York Heart Association) 
No prior treatment with Ventavis or other active treatments for primary pulmonary hypertension within 6 weeks of date of study inclusion (unless otherwise advised by Bayer Schering Pharma) 

NCT00250640_inc_T1
Drug
Ventavis
NCT00250640_inc_T2
Condition
primary pulmonary hypertension
NCT00250640_inc_T3
Condition
Idiopathic Pulmonary Arterial Hypertension
NCT00250640_inc_T4
Condition
Familial Pulmonary Arterial Hypertension
NCT00250640_inc_T5
Scope
Idiopathic Pulmonary Arterial Hypertension or Familial Pulmonary Arterial Hypertension
NCT00250640_inc_T6
Measurement
NYHA functional class
NCT00250640_inc_T7
Value
III
NCT00250640_inc_T8
Procedure
treatment with Ventavis
NCT00250640_inc_T9
Condition
primary pulmonary hypertension
NCT00250640_inc_T10
Procedure
treatments
NCT00250640_inc_T11
Qualifier
for primary pulmonary hypertension
NCT00250640_inc_T12
Temporal
within 6 weeks of date of study inclusion
NCT00250640_inc_T13
Negation
No
NCT00250640_inc_T14
Scope
treatment with Ventavis or other active treatments for primary pulmonary hypertension
NCT00250640_inc_T15
Multiplier
long-term